drugset

drugset / Trial / NCT01130753

Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer

NCT01130753 ↗

Phase 2 Completed 43 enrolled Samsung Medical Center

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study propose neoadjuvant chemotherapeutic role by erlotinib.

Timeline

Start: 2007-01
Primary completion: 2010-12
Completion: 2012-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	150 mg	Oral

Indications